Abstract 1606P
Background
Sarcopenia refers to the loss of muscle mass and strength that occurs with aging and due to some medical conditions like cancer. Depression and inability to eat without assistance are common effects documented in cancer patients with sarcopenia. As a result, the goal of this study was to look into the relationship between sarcopenia, depression, and modes of feeding.
Methods
During the period beginning in January 2023 and ending in April 2023, cancer patients participated in a retrospective study. There has been a total of 150 participants enrolled in the trial, all of whom have been diagnosed with cancer. These people were enrolled in Mayo Hospital's Palliative Care Cancer Department in order to receive treatment. The Patient Health Questionnaire (PHQ-9) was used to determine the presence of depressive symptoms. The SARC-F was utilized to assess sarcopenia across all five dimensions. A self-report measure was utilized to assess modes of feeding [options include: 1) unable to eat without assistance 2) (self-fed with some difficulty, and 3) self-fed without any problem]. Sarcopenia, major depressive disorder, and feeding modes were studied using correlation analysis.
Results
We have observed a significant and negative association between modes of feeding and depression (r=-0.459, p<0.01), SARC1=Strength (r = -0.326, p<0.01), SARC2=Assistance in walking (r = -0.196, p<0.05), and SARC3=Rise from a chair (r = -0.238, p<0.01). These findings show that cancer patients are unable to eat without assistance when they suffer from sarcopenia which ultimately leads to more depressive symptoms.
Conclusions
Sarcopenia has a negative impact on the quality of life of patients, leading to depression and dependence on daily activities like self-eating which further complicates management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2018P - Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Presenter: Jun Zhao
Session: Poster session 05
2019P - Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Presenter: Mónica Esteban García
Session: Poster session 05
2020P - Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2021P - Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2022P - ALBA project: Prognostic impact of laterality in small cell lung cancer
Presenter: Lorenza Landi
Session: Poster session 05
2024P - Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Presenter: Manuel Dómine
Session: Poster session 05
2025P - Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers
Presenter: Li Liu
Session: Poster session 05
2026P - Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Presenter: Lionel Falchero
Session: Poster session 05
2027P - Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis
Presenter: Patsy Lee
Session: Poster session 05